复方鳖甲软肝片联合恩替卡韦治疗乙肝肝硬化的疗效

Clinical observation of compound biejiaruangan tablets combined with entecavir in treatment of liver cirrhosis

目的观察复方鳖甲软肝片治疗乙肝肝硬化的临床疗效。方法将100例乙肝肝硬化患者随机分为治疗组和对照组，治疗组口服复方鳖甲软肝片联合恩替卡韦，对照组单用恩替卡韦等常规药，疗程均为6个月。观察治疗前后患者的临床表现、肝功能、乙肝病毒基因定量（HBV-DNA）、肝纤维化指标。结果治疗组在改善临床症状，恢复肝功能方面优于对照组（P〈0．05），HBV—DNA阴转差异未见统计学意义（P〉0．05），肝纤维化指标明显改善（P〈0．05）。结论复方鳖甲软肝片联合恩替卡韦治疗乙肝肝硬化能有效地改善临床症状，恢复肝功能，使患者HBV—DNA阴转，提高生存率。

Objective To observe the clinical effect of compound biejiaruangan tablets on liver cirrhosis. Methods One hundred cases of liver cirrhosis were randomly divided into treatment group and control group, the treatment group was treated with compound biejiaruangan tablets joint with entecavir, and the control group was given entecavir alone and other conventional drugs. The treatment course was 6 months. The clinical manifestations before and after treatment, liver function, hepatitis B virus quantitative gene（HBV-DNA） , liver fibrosis indexes were observed. Results Clinical symptoms and liver function recovery of the treatment group were better than those of the control group, there were significant difference （P 〈 0.05 ） , there was no significant difference in HBV-DNA negative conversion rate （ P 〉 0. 05 ）, liver fibrosis improved significantly （ P 〈 0.05 ）. Conclusions Compound biejiaruangan tablets combined with entecavir in treatment of hepatitis B cirrhosis can effectively improve the clinical symptoms, restore liver function, make HBV-DNA negative conversion, and improve the survival rate.